Gilde Healthcare Partners awarded European Venture Fundraising of the year - Gilde Healthcare

Gilde Healthcare Partners awarded European Venture Fundraising of the year

11. Februar 2008

Utrecht – Gilde Healthcare Partners, a rapidly growing European venture capital firm, has received the Venture Fundraising of the Year Award from the European Venture Capital Journal. The Award was for the successful closing of Gilde Healthcare II (GHC II), its EUR 150 million venture fund, in 2007. The original target for GHC II was EUR 125 million.

GHC II is one of the largest venture funds raised to invest in European healthcare opportunities. GHC II was backed by current investors in Gilde Healthcare Funds, who were joined by a small select group of new investors. Investors were attracted by Gilde Healthcare Partners’ excellent investment track record which has seen it achieve six successful exits in the past two years.
 
Gilde Healthcare Partners invests in strong professional management teams developing therapeutics, diagnostics, medical devices and enabling technologies. Gilde creates significant value for both its investors and the driven entrepreneurs it backs by selectively investing in companies with well thought-out business models. The fund invests at all stages of a company’s development from seed stage to pre-IPO rounds. Gilde’s investments range from EUR 1 million up to EUR 15 million per investee company after all private rounds of financing. 
Founded in 2000, Gilde Healthcare Partners is headquartered in Utrecht, The Netherlands with representatives in London and Madrid. Gilde Healthcare Partners currently has over EUR 275 million (USD 400 million) under management. Gilde is an ambitious builder of healthcare businesses across Europe. Companies that Gilde Healthcare Partners has pro-actively supported span all aspects of healthcare and include Ablynx (Belgium), Agendia (Netherlands), AMT (Netherlands), Ascendis Pharma (Denmark), Chroma Therapeutics (UK), Glycart (Switzerland), Innate Pharma (France), Santaris Pharma (Denmark) and Symphogen (Denmark). For a full list of Gilde’s portfolio companies please visit the website.

Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start up Facility

Mehr neuigkeiten

Gilde Healthcare backed MedTech Group acquires precision surgical instruments and implants contract manufacturer Rudischhauser

Gilde Healthcare’s Surgical Instrument Contract Manufacturing Group (“the Group”) has acquired Rudischhauser Surgical Instruments Manufacturing GmbH (“Rudischhauser”), marking a significant milestone in the creation of a leading contract manufacturing group for precision surgical instruments. Rudischhauser...
26. Januar 2026

Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease

First dose-expansion patient successfully received SB-007  SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations  SB-007 granted FDA Fast Track designation, following previously received Orphan Drug...
9. Januar 2026

Gilde Healthcare erwirbt einen Mehrheitsanteil an Physio CKI, einer physiotherapeutischen Praxisgruppe, von Kapital 1852

Der Private Equity Fonds von Gilde Healthcare gibt den Erwerb der Mehrheitsanteile an Physio CKI von Kapital 1852 bekannt. Physio CKI ist eine wachstumsstarke Gruppe von Physiotherapiepraxen mit Hauptsitz in Köln. Gründer und Geschäftsführer Chaled...
22. Dezember 2025